Advanced in Waldenstrom Macroglobulinemia

Dr. Anita B. D'souza

Hematology Oncology | Hematology | Oncology
The Medical College Of Wisconsin Inc
8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
Accepting New Patients
Offers Telehealth
17 Years of Experience
Advanced in Waldenstrom Macroglobulinemia
The Medical College Of Wisconsin Inc
8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anita D'souza is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. D'souza has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. Her top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Tissue Biopsy. Dr. D'souza is currently accepting new patients.

Her clinical research consists of co-authoring 236 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Waldenstrom Macroglobulinemia.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MN
Hospital Affiliations
Froedtert Memorial Lutheran Hospital
Holy Family Memorial
Languages Spoken
English
Hindi
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Network Health
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

THE MEDICAL COLLEGE OF WISCONSIN INC
8701 Watertown Plank Rd, Room 4041 Mfrc, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Enrollment Status: Active_not_recruiting
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drugs: Daratumumab, Pomalidomide, Dexamethasone
Study Phase: Phase 2
An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drugs: TAK-079, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

236 Total Publications

Multiple myeloma incidence, transplant utilization, and mortality- impact of social vulnerability.
Multiple myeloma incidence, transplant utilization, and mortality- impact of social vulnerability.
Journal: Bone marrow transplantation
Published: August 01, 2025
Similar Doctors
Dean G. Tsarwhas
Distinguished in Waldenstrom Macroglobulinemia
Dr. Dean G. Tsarwhas
Hematology | Oncology
Distinguished in Waldenstrom Macroglobulinemia
Dr. Dean G. Tsarwhas
Hematology | Oncology
1000 N Westmoreland Rd Level 1, Pavilion A, 
Lake Forest, IL 
 (56.4 miles away)
847-582-2134
Experience:
38+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dean Tsarwhas is a Hematologist and an Oncologist in Lake Forest, Illinois. Dr. Tsarwhas has been practicing medicine for over 38 years and is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Sezary Syndrome, Paget Disease of the Breast, Angiosarcoma, and Large-Cell Immunoblastic Lymphoma.

Distinguished in Waldenstrom Macroglobulinemia
Dr. Sameer Tolay
Hematology Oncology | Hematology | Oncology
Distinguished in Waldenstrom Macroglobulinemia
Dr. Sameer Tolay
Hematology Oncology | Hematology | Oncology

Agnesian Healthcare Inc

480 E Division St, 
Fond Du Lac, WI 
 (54.7 miles away)
920-926-4100
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Sameer Tolay is a Hematologist Oncology specialist and a Hematologist in Fond Du Lac, Wisconsin. Dr. Tolay is rated as an Advanced provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Waldenstrom Macroglobulinemia, Multiple Myeloma, Muscle Invasive Bladder Cancer, and Non-Muscle Invasive Bladder Cancer. Dr. Tolay is currently accepting new patients.

Parameswaran N. Hari
Advanced in Waldenstrom Macroglobulinemia
Dr. Parameswaran N. Hari
Hematology Oncology | Hematology | Oncology
Advanced in Waldenstrom Macroglobulinemia
Dr. Parameswaran N. Hari
Hematology Oncology | Hematology | Oncology
9200 W Wisconsin Ave, Hematology And Oncology, 
Milwaukee, WI 
 (0.2 miles away)
414-805-0505
Languages Spoken:
English, Hindi, Malayalam, Tamil, Urdu
See accepted insurances
Accepting New Patients

Parameswaran Hari is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Hari is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Primary Amyloidosis, Bone Marrow Transplant, and Splenectomy. Dr. Hari is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. D'souza's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile